The U.S. Department of Health and Human Services will provide approximately $11 million to support the first U.S.-based fill and finish manufacturing of JYNNEOS, a vaccine approved to prevent smallpox and monkeypox.
In a Phase II trial of participants with hepatic disease associated with congenital alpha1-antitrypsin deficiency, subcutaneous administration of fazirsitran, an investigational RNA interference therapeutic, reduced both serum and hepatic levels of the mutant hepatotoxic AAT protein Z-AAT, with concurrent improvements in enzymatic and histological markers of liver function.
Subcutaneous administration of marstacimab, an investigational human monoclonal antibody targeting tissue factor pathway inhibitor, resulted in a roughly 10-fold lower annualized bleeding rate in 26 hemophilia patients than comparable control individuals in previous clinical trials who were treated on-demand with recombinant factor replacement therapy.
Dutch investigators conducted a systematic review and meta-analysis of studies on the effectiveness of IVIG treatment of this specific population.
Sanofi's fitusiran significantly reduced bleeding in a Phase III multinational study in adults and adolescents with hemophilia A or B, with or without inhibitors.
NIAID has launched an early-stage clinical trial to evaluate an investigational preventive vaccine for Epstein-Barr virus (EBV).
A new study shows treatment with IVIG shows promise for children and young adults with Down syndrome regression disorder (DSRD).
Despite technical challenges, some companies are working on making a combination COVID and flu vaccine.
New data from a Phase II clinical trial of Valneva SE and Pfizer Inc.’s Lyme disease vaccine candidate, VLA15, shows it produced strong immune responses, prompting preparations for a Phase III study in the third quarter of 2022.
NIAID has launched a Phase I clinical trial evaluating three experimental HIV vaccines based on a mRNA platform — a technology used in several approved COVID-19 vaccines.
A clinical trial of the Vaxina (the CF33-hNIS virus) designed to kill cancer cells has begun.
According to CDC, this season’s influenza (flu) vaccines offered meager protection against mild cases of influenza.